Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation
Acta Haematologica · 2024 · 147 (3) · 325-332
DOI: 10.1159/000534315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 12.10.2023. Verfasst von Lia Minculescu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphocyte Transfusion, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Abstract (Originalsprache)
Introduction
Donor lymphocyte infusion (DLI) is used to induce remission in patients who relapse after allogeneic stem cell transplantation (allo-HSCT). During the last decade, the hypomethylating agent Azacitidine has been used together with DLI for a synergistic graft-versus-leukemia (GVL) effect. Here, we report results of DLI/Azacitidine treatment from a retrospective single-center study.
Methods
Fifty AML/MDS patients treated for relapse after allo-HSCT between 2001 and 2020 with DLI at the Department of Hematology, at Rigshospitalet, Copenhagen University Hospital were included for analyses. A subgroup of patients who obtained complete remission (CR) after reinduction chemotherapy, received DLI in combination with low-dose (32 mg/m2) Azacitidine.
Results
Overall survival in all patients after DLI treatment was 59% at 2 years and 20% at 5 years. Relapse-free survival in patients in CR prior to DLI was 32% after 2 years and 7% after 5 years. In the DLI + low-dose-Azacitidine group, 5-year relapse-free survival was 40%.
Conclusion
DLI remains an effective treatment in post-transplant relapse leaving one-fifth of patients’ long-term survivors. Our results support the concomitant use of low-dose Azacitidine in the future use of DLI in order to enhance the GVL effect of donor lymphocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Infectious Diseases, PERSIMUNE, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Quality, StemMedical A/S, Soeborg, Denmark.
Zitieren
APA
Minculescu, L., Reekie, J., Petersen, S. L., Kornblit, B. T., Schjoedt, I., Andersen, N. S., Andersen, L. P., Fischer-Nielsen, A., Haastrup, E. K., Friis, L. S., & Sengelov, H. (2024). Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation. Acta Haematologica, 147(3), 325-332. https://doi.org/10.1159/000534315
Vancouver
Minculescu L, Reekie J, Petersen SL, Kornblit BT, Schjoedt I, Andersen NS, et al. Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation. Acta Haematologica. 2024;147(3):325-332. doi:10.1159/000534315
BibTeX
@article{Minculescu2024,
author = {Minculescu, Lia and Reekie, Joanne and Petersen, Soeren Lykke and Kornblit, Brian Thomas and Schjoedt, Ida and Andersen, Niels Smedegaard and Andersen, Lisbeth Pernille and Fischer-Nielsen, Anne and Haastrup, Eva Kannik and Friis, Lone Smidstrup and Sengelov, Henrik},
title = {Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation},
journal = {Acta Haematologica},
year = {2024},
volume = {147},
number = {3},
pages = {325--332},
doi = {10.1159/000534315}
}
EUVIMED